Stocks Health care CNTB
NASDAQ · Health careConnect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd brought in $3M of revenue over the twelve months to June 30, 2026. It posted a net loss of $69M. In fiscal 2025 capital spending exceeded operating cash flow by $51.6M. At June 30, 2026 it held $27M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Connect Biopharma Holdings Ltd
- Net worth
- Connect Biopharma Holdings Ltd has a market value (market cap) of $44.2M at the latest share price, and shareholders' equity of $26.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $64K (-99.8% year on year), with a net loss of $55.5M. Over the 12 months to June 30, 2026: revenue $3M, net loss $69M.
- Cash flow
- In fiscal 2025 operations used $51.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Connect Biopharma Holdings Ltd's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Connect Biopharma Holdings Ltd does
Connect Biopharma Holdings Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CNTB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $64K | -$55.5M | -$1.00 | -$51.6M |
| 2024 | $26M | -$15.6M | -$0.28 | -$24.4M |
| 2023 | $0 | -$62.1M | -$1.13 | -$47.8M |
| 2022 | n/a | -$118.1M | -$2.25 | -$105.9M |
| 2021 | n/a | -$202.3M | -$4.06 | -$88.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CNTB ranks in Health care
Latest SEC filings
What Connect Biopharma Holdings Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Passive stake changed SCHEDULE 13G/A
- October 6, 2026Passive stake (5% or more) SCHEDULE 13G
- September 30, 2026
- September 15, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5,667% to $2.8M versus the same quarter last year; diluted EPS -$0.27 versus -$0.23.
- August 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Form F-3 filing F-3
Insider trades
What the people running Connect Biopharma Holdings Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Liu Jean IDirector | Received as pay | 8,984 | - |
| September 30, 2026 | Xanthopoulos Kleanthis GabrielDirector | Received as pay | 5,000 | - |
| June 30, 2026 | Liu Jean IDirector | Received as pay | 6,718 | - |
| June 30, 2026 | Xanthopoulos Kleanthis GabrielDirector | Received as pay | 3,738 | - |
| May 29, 2026 | Huang JamesDirector | Boughtindirect | 150,000 | $371.6K |
| March 31, 2026 | Liu Jean IDirector | Received as pay | 5,061 | - |
| March 31, 2026 | Xanthopoulos Kleanthis GabrielDirector | Received as pay | 2,816 | - |
| March 31, 2026 | Huang JamesDirector | Boughtindirect | 1,160,000 | $4M |
Who owns CNTB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Panacea Innovation Limited13D, may seek influence with 3 related filers | 21.2% | April 1, 2026 |
| Wubin Pan13G, passive with 1 related filers | 9.6% | April 14, 2026 |
| Ikarian Capital, LLC13G, passive with 1 related filers | 6.9% | August 14, 2026 |
| Braden M Leonard13G, passive with 1 related filers | 6.77% | October 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 56 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Ikarian Capital, LLC | 4,538,534 | -849,952 |
| 683 Capital Management, LLC | 1,285,000 | +385,000 |
| Boothbay Fund Management, LLC | 973,732 | -260,850 |
| BlackRock, Inc. | 871,653 | new |
| Perceptive Advisors LLC | 792,696 | 0 |
| ADAR1 Capital Management, LLC | 700,000 | -42,400 |
| BML Capital Management, LLC | 573,287 | +164,400 |
| Silverarc Capital Management, LLC | 545,000 | new |
| Richmond Brothers, Inc. | 535,612 | +59,028 |
| Knott David M Jr | 444,862 | +57,027 |
| Stonepine Capital Management, LLC | 364,254 | +54,254 |
| Marshall Wace, Llp | 335,642 | +269,629 |
| Geode Capital Management, LLC | 257,454 | +225,325 |
| Two Sigma Investments, LP | 199,381 | +151,916 |
| Diadema Partners LP | 196,985 | -3,705 |
| Burkehill Global Management, LP | 150,000 | 0 |
| Vanguard Portfolio Management LLC | 102,755 | new |
| Susquehanna International Group, Llp | 102,148 | -176,660 |
| Renaissance Technologies LLC | 87,300 | -33,400 |
| Northern Trust Corp | 82,862 | new |
Insiders
3 insiders reported holding 13,422,317 shares in total, about $9.4M at the last price.
| Holder | Shares |
|---|---|
| Huang JamesDirector | 13,310,00013,310,000 held indirectly |
| Xanthopoulos Kleanthis GabrielDirector | 91,554 |
| Liu Jean IDirector | 20,763 |
Questions about CNTB
What does Connect Biopharma Holdings Ltd do?
Connect Biopharma Holdings Ltd is a company in the Health care sector, listed on NASDAQ as CNTB. Its shares trade on NASDAQ under the ticker CNTB.
What is Connect Biopharma Holdings Ltd's net worth?
Connect Biopharma Holdings Ltd has a market value (market cap) of $44.2M at the latest share price, and shareholders' equity of $26.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Connect Biopharma Holdings Ltd profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $69M on revenue of $3M.
How much revenue does Connect Biopharma Holdings Ltd make?
Over the twelve months to June 30, 2026 Connect Biopharma Holdings Ltd reported revenue of $3M.
When did Connect Biopharma Holdings Ltd last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 3, 2026.
When is Connect Biopharma Holdings Ltd's next earnings report?
Connect Biopharma Holdings Ltd's next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CNTB with
Follow CNTB
Get an email when Connect Biopharma Holdings Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Connect Biopharma Holdings Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.